Skip to main content

Are you a legal professional? Visit our professional site

Search for legal issues
For help near (city, ZIP code or county)
Please enter a legal issue and/or a location

Risperdal News

October 20, 2006: Group Urges Caution on Use of Risperdal to Treat Autism
The U.S. Food and Drug Administration (FDA) recently approved Risperdal for the symptomatic treatment of irritability in autistic children and adolescents. In response, the National Autism Association (NAA) is urging parents and health care providers to carefully research the potential side effects of Risperdal use by autistic children. According to the NAA, documented side effects include lactation (in both boys and girls), weight gain, and development of tardive dyskinesia, an often irreversible movement disorder.

July 13, 2006: Mass-Tort Designation Sought for Antipsychotic Drug Lawsuits
In a Middlesex County (New Jersey) court, 235 claims have been filed against the manufacturers of the antipsychotic drugs Risperdal, Seroquel, and Zyprexa. A superior court judge has asked the New Jersey Supreme Court to combine litigation into a single mass tort. The drugs at issue have been allegedly linked to the occurrence of harmful medical conditions, including diabetes.

July 13, 2006: Risperdal May Be Liked to Pituitary Tumor Development
Research from Duke Medical Center and the U.S. Food and Drug Administration (FDA) shows a possible connection between Risperdal use and the development of pituitary tumors. Risperdal was linked to 70% of the pituitary tumors reported by users of seven different antipsychotic medicines that were part of this systematic study. Although the study suggests a connection between Risperdal use and pituitary tumor development, researchers say that it does not prove causation, and that further studies are needed.

April, 2006: FDA Alert - Risperdal Use in Older Patients
The FDA issued an alert announcing its findings that older patients treated with atypical antipsychotics (such as Risperdal) for dementia had a higher chance for death than patients who did not take the medicine. The FDA further stated that treatment of dementia with atypical antipsychotics is not an approved use, and has asked the manufacturers of these medicines to change their labels to include this important information. Click here to read this alert and other information about Risperdal.

Next Steps

Contact a qualified product liability attorney to make sure your rights are protected.

Help Me Find a Do-It-Yourself Solution

Find a Lawyer

More Options